Raleigh Capital Management’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-624
Closed -$5.78K – 1055
2023
Q4
$5.78K Buy
624
+92
+17% +$752 ﹤0.01% 714
2023
Q3
$5.38K Buy
532
+76
+17% +$907 ﹤0.01% 677
2023
Q2
$5.7K Buy
456
+149
+49% +$1.77K ﹤0.01% 618
2023
Q1
$3.58K Buy
+307
New +$3.91K ﹤0.01% 681

Other funds holding HCAT

Raleigh Capital Management's HCAT Position: Q1 2024 in Review

Raleigh Capital Management sold out of Health Catalyst (HCAT) in Q1 2024, closing a stake of 624 shares — an estimated $5.78K sold.

Raleigh Capital Management first reported a position in HCAT in Q1 2023 and held it in 4 quarters. The position peaked at $5.78K in Q4 2023. 174 funds tracked by Wall St. Rank hold HCAT as of Q1 2024.

  • Raleigh Capital Management reported no remaining Health Catalyst position as of Q1 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 624 Health Catalyst shares in Q1 2024, an estimated $5.78K.
  • Raleigh Capital Management first reported a position in Health Catalyst in Q1 2023 and held it in 4 quarters.
  • Raleigh Capital Management's Health Catalyst position peaked at $5.78K in Q4 2023.
  • 174 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2024.

Based on Raleigh Capital Management's 13F filing for Q1 2024, filed 13 May 2024.